Merck & Co delays rolofylline in heart failure
This article was originally published in Scrip
Executive Summary
Merck & Co's acute heart failure drug rolofylline (MK-7418) has failed in a Phase III trial, preliminary results show. The company no longer plans to seek regulatory approval for the drug this year.